scholarly journals The Prognostic Role of the Class III β-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis

PLoS ONE ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. e93997 ◽  
Author(s):  
Yan-Long Yang ◽  
Xiu-Ping Luo ◽  
Lei Xian
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Class Iii ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Nsclc Patients ◽  
Β Tubulin

scholarly journals Prognostic Role of MicroRNA Let-7 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Xiaoting Zhang ◽  
Huaning Kang ◽  
Guihong Chen ◽  
Xiaofeng Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Cochrane Library ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Nsclc Patients

Abstract BackgroundRecent studies have shown that MicroRNAs can be used as potential biomarkers to the prognosis in non-small cell lung cancer (NSCLC). Hence, we conducted this meta-analysis to evaluate the prognostic role of microRNA let-7 in NSCLC patients.MethodsPubMed, Web of Science, Medline and the Cochrane Library were searched for relevant studies. Eligible studies were met specific inclusion and exclusion criteria. Stata 15.1 was used to calculate the pooled parameters.ResultsA total of 11 studies involving 2278 NSCLC patients were included in this meta-analysis. Subgroup analyses established that the heterogeneity was connected with ethnicity and follow-up time. The results suggested that the low expression of microRNA let-7 indicates a poor overall survival rate, with a hazard ratio value of 0.99 (95% CI: 0.64-1.34, P <0.05).ConclusionsLow expression of microRNA let-7 is closely related to the poor prognosis of NSCLC, so microRNA let-7 may become a new biomarker to evaluate the prognosis of NSCLC patients.

scholarly journals Prognostic Role of MicroRNA-21 in Non-small Cell Lung Cancer: a Meta-analysis

2012 ◽  
Vol 13 (5) ◽  
pp. 2329-2334 ◽  
Author(s):  
Xue-Lei Ma ◽  
Lei Liu ◽  
Xiao-Xiao Liu ◽  
Yun Li ◽  
Lei Deng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role

scholarly journals The Prognostic Role of mTOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (2) ◽  
pp. e0116771 ◽  
Author(s):  
Lei Li ◽  
Dan Liu ◽  
Zhi-Xin Qiu ◽  
Shuang Zhao ◽  
Li Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role

scholarly journals Prognostic role of dysregulated circRNAs in patients with non-small cell lung cancer: a meta-analysis

2020 ◽  
Vol 12 (3) ◽  
pp. 823-829
Author(s):  
Quanwa Bao ◽  
Feng Li ◽  
Houzhen Zheng ◽  
Shaobo Chen ◽  
Xiao Song
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role

Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer

2020 ◽  
Vol 16 (26) ◽  
pp. 1957-1967
Author(s):  
Chunliu Meng ◽  
Xingping Ge ◽  
Jia Tian ◽  
Jia Wei ◽  
Lujun Zhao
Keyword(s):  
Lung Cancer ◽  
Liver Metastases ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Adrenal Metastases ◽  
Nsclc Patients ◽  
Egfr Tkis

Aim: To evaluate the prognostic role of EGFR mutations in patients with multi-site metastases from non-small-cell lung cancer (NSCLC). Patients & methods: A total of 215 advanced NSCLC patients with multi-site metastases were included. The overall survival (OS) was the primary end point. Results: EGFR tyrosine kinase inhibitors (TKIs) significantly improved the OS in patients with brain metastases (p = 0.031) and bone metastases (p = 0.048). Meanwhile, it prolonged the OS in patients with lung or adrenal metastases, but not in patients with liver metastases. However, in patients without liver metastases, EGFR TKIs significantly improved the OS (p < 0.001). Conclusion: EGFR TKIs improved the prognosis in NSCLC patients with brain, bone, lung and adrenal metastases, but not in patients with liver metastases.

Sign in / Sign up

Export Citation Format

Share Document